[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frFjeTEE_k8PXFp9-TgIgQjLM9EOgkXMK2ZWSOr5BPjM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"Clinica Universidad de Navarra, Universidad de Navarra",[4],159,false,33,3,73840,4,113,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Obesity",11,{"name":18,"count":19},"Overweight and Obesity",6,{"name":21,"count":19},"Overweight",{"name":23,"count":11},"Surgery",{"name":25,"count":11},"Breast Cancer",{"name":27,"count":9},"Prostate Cancer",{"name":29,"count":9},"Weight Loss",{"name":31,"count":9},"Microbiota",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT07113379","Study for Prevention of Cervical Cancer in Spain","2026-01","Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain.",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07284277","TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","2027-03","TTFields concomitant with modFOLFIRINOX",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07059676","Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer","2027-12-31","Zejula",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07424092","Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors","2029-05","DNX-2401",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,104,126,150,172,209,237,255,273,303,321,339,357,375,413,438,464,501,537,562,590,614,639,662,688,714,740,758,783,808,835,860,878,896,922,946,969,987,1014,1032,1055,1082,1100,1118,1136,1160,1187,1212,1237,1261,1287,1305,1331,1369,1395,1413,1431,1449,1467,1495],{"intervention":52,"totalTrials":62,"cells":63},2,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":81,"PHASE3":98,"PHASE4":100,"NA":102},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[69],{"nctId":70,"briefTitle":71,"status":72,"phases":73,"primaryCompletion":74,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":80},"NCT03178032","Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas","COMPLETED",[55],"2021-01-31","2017-05-26",12,[78,79],"Brainstem Glioma","Neoadjuvant Therapy",[52],{"trials":82,"activeCount":97,"soonestReadout":51},[83],{"nctId":49,"briefTitle":50,"status":84,"phases":85,"primaryCompletion":51,"completion":51,"start":86,"enrollment":87,"conditions":88,"interventions":96},"RECRUITING",[56],"2026-05-12",39,[89,90,91,92,93,94,95],"High Grade Glioma","Ependymoma","Embryonal Tumor of Brain","Recurrence","Refractory","Pediatric","Young Adult",[52],1,{"trials":99,"activeCount":66},[],{"trials":101,"activeCount":66},[],{"trials":103,"activeCount":66},[],{"intervention":42,"totalTrials":97,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":107,"activeCount":66},[],{"trials":109,"activeCount":66},[],{"trials":111,"activeCount":97,"soonestReadout":41},[112],{"nctId":39,"briefTitle":40,"status":84,"phases":113,"primaryCompletion":41,"completion":41,"start":114,"enrollment":115,"conditions":116,"interventions":119},[55,56],"2025-10-14",30,[117,118],"Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma",[42],{"trials":121,"activeCount":66},[],{"trials":123,"activeCount":66},[],{"trials":125,"activeCount":66},[],{"intervention":37,"totalTrials":97,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":138},{"trials":129,"activeCount":66},[],{"trials":131,"activeCount":66},[],{"trials":133,"activeCount":66},[],{"trials":135,"activeCount":66},[],{"trials":137,"activeCount":66},[],{"trials":139,"activeCount":97,"soonestReadout":36},[140],{"nctId":34,"briefTitle":35,"status":141,"phases":142,"primaryCompletion":36,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":149},"NOT_YET_RECRUITING",[],"2026-10","2025-10",200,[147,148],"Cervical Cancer Screening","HPV Vaccination",[37],{"intervention":47,"totalTrials":97,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":162},{"trials":153,"activeCount":66},[],{"trials":155,"activeCount":66},[],{"trials":157,"activeCount":66},[],{"trials":159,"activeCount":66},[],{"trials":161,"activeCount":66},[],{"trials":163,"activeCount":97,"soonestReadout":46},[164],{"nctId":44,"briefTitle":45,"status":141,"phases":165,"primaryCompletion":46,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},[],"2028-03-31","2025-07-25",120,[170],"Advanced Ovarian Cancer",[47],{"intervention":173,"totalTrials":62,"cells":174},"Dexmedetomidine",{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":207},{"trials":176,"activeCount":66},[],{"trials":178,"activeCount":66},[],{"trials":180,"activeCount":66},[],{"trials":182,"activeCount":66},[],{"trials":184,"activeCount":66},[185,195],{"nctId":186,"briefTitle":187,"status":72,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":76,"conditions":191,"interventions":193},"NCT02256319","Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators",[58],"2015-12","2014-09",[192],"Parkinson's Disease",[173,194],"Propofol",{"nctId":196,"briefTitle":197,"status":198,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":76,"conditions":203,"interventions":206},"NCT02982512","Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease","UNKNOWN",[58],"2018-09","2018-12","2017-05-01",[173,204,205],"Deep Brain Stimulation","Parkinson Disease",[173],{"trials":208,"activeCount":66},[],{"intervention":210,"totalTrials":97,"cells":211},"Acetylcysteine",{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":235},{"trials":213,"activeCount":66},[],{"trials":215,"activeCount":66},[],{"trials":217,"activeCount":66},[],{"trials":219,"activeCount":66},[],{"trials":221,"activeCount":66},[222],{"nctId":223,"briefTitle":224,"status":72,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":233},"NCT01223326","N-acetylcysteine to Reduce Ischemia\u002FReperfusion Injury in Liver Resection",[58],"2007-10","2007-12","2003-01",46,[231,232],"Hepatectomy","Reperfusion Injury",[210,234],"Saline",{"trials":236,"activeCount":66},[],{"intervention":234,"totalTrials":97,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":253},{"trials":240,"activeCount":66},[],{"trials":242,"activeCount":66},[],{"trials":244,"activeCount":66},[],{"trials":246,"activeCount":66},[],{"trials":248,"activeCount":66},[249],{"nctId":223,"briefTitle":224,"status":72,"phases":250,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":251,"interventions":252},[58],[231,232],[210,234],{"trials":254,"activeCount":66},[],{"intervention":194,"totalTrials":97,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":66},[],{"trials":260,"activeCount":66},[],{"trials":262,"activeCount":66},[],{"trials":264,"activeCount":66},[],{"trials":266,"activeCount":66},[267],{"nctId":186,"briefTitle":187,"status":72,"phases":268,"primaryCompletion":189,"completion":189,"start":190,"enrollment":76,"conditions":269,"interventions":270},[58],[192],[173,194],{"trials":272,"activeCount":66},[],{"intervention":274,"totalTrials":97,"cells":275},"Vancomycin antimicrobial-lock solution",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":301},{"trials":277,"activeCount":66},[],{"trials":279,"activeCount":66},[],{"trials":281,"activeCount":66},[],{"trials":283,"activeCount":66},[],{"trials":285,"activeCount":66},[286],{"nctId":287,"briefTitle":288,"status":198,"phases":289,"primaryCompletion":290,"completion":189,"start":291,"enrollment":292,"conditions":293,"interventions":296},"NCT01592032","Concentration of Antimicrobials in Catheter-lock Solutions",[58],"2015-01","2012-05",125,[294,295],"Catheter-Related Infections","Bacteremia.",[274,297,298,299,300],"Teicoplanin antimicrobial-lock solution","Linezolid antimicrobial-lock solution","Daptomycin antimicrobial-lock solution","Tigecycline antimicrobial-lock solution",{"trials":302,"activeCount":66},[],{"intervention":297,"totalTrials":97,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":306,"activeCount":66},[],{"trials":308,"activeCount":66},[],{"trials":310,"activeCount":66},[],{"trials":312,"activeCount":66},[],{"trials":314,"activeCount":66},[315],{"nctId":287,"briefTitle":288,"status":198,"phases":316,"primaryCompletion":290,"completion":189,"start":291,"enrollment":292,"conditions":317,"interventions":318},[58],[294,295],[274,297,298,299,300],{"trials":320,"activeCount":66},[],{"intervention":298,"totalTrials":97,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":337},{"trials":324,"activeCount":66},[],{"trials":326,"activeCount":66},[],{"trials":328,"activeCount":66},[],{"trials":330,"activeCount":66},[],{"trials":332,"activeCount":66},[333],{"nctId":287,"briefTitle":288,"status":198,"phases":334,"primaryCompletion":290,"completion":189,"start":291,"enrollment":292,"conditions":335,"interventions":336},[58],[294,295],[274,297,298,299,300],{"trials":338,"activeCount":66},[],{"intervention":299,"totalTrials":97,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":355},{"trials":342,"activeCount":66},[],{"trials":344,"activeCount":66},[],{"trials":346,"activeCount":66},[],{"trials":348,"activeCount":66},[],{"trials":350,"activeCount":66},[351],{"nctId":287,"briefTitle":288,"status":198,"phases":352,"primaryCompletion":290,"completion":189,"start":291,"enrollment":292,"conditions":353,"interventions":354},[58],[294,295],[274,297,298,299,300],{"trials":356,"activeCount":66},[],{"intervention":300,"totalTrials":97,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":373},{"trials":360,"activeCount":66},[],{"trials":362,"activeCount":66},[],{"trials":364,"activeCount":66},[],{"trials":366,"activeCount":66},[],{"trials":368,"activeCount":66},[369],{"nctId":287,"briefTitle":288,"status":198,"phases":370,"primaryCompletion":290,"completion":189,"start":291,"enrollment":292,"conditions":371,"interventions":372},[58],[294,295],[274,297,298,299,300],{"trials":374,"activeCount":66},[],{"intervention":376,"totalTrials":62,"cells":377},"Bemiparin",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":395,"PHASE4":409,"NA":411},{"trials":379,"activeCount":66},[],{"trials":381,"activeCount":66},[],{"trials":383,"activeCount":66},[384],{"nctId":385,"briefTitle":386,"status":387,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":87,"conditions":392,"interventions":394},"NCT00324558","Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)","TERMINATED",[56],"2010-02","2010-09","2005-06",[393],"Carcinoma, Small Cell",[376],{"trials":396,"activeCount":66},[397],{"nctId":398,"briefTitle":399,"status":387,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":408},"NCT00311896","Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)",[57],"2009-02","2010-12","2005-07",402,[406,407],"Cancer","Thrombosis",[376],{"trials":410,"activeCount":66},[],{"trials":412,"activeCount":66},[],{"intervention":414,"totalTrials":97,"cells":415},"methylphenidate",{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":422,"PHASE4":434,"NA":436},{"trials":417,"activeCount":66},[],{"trials":419,"activeCount":66},[],{"trials":421,"activeCount":66},[],{"trials":423,"activeCount":66},[424],{"nctId":425,"briefTitle":426,"status":387,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT01773837","Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients",[57],"2018-02","2012-01",100,[432],"Asthenia",[414],{"trials":435,"activeCount":66},[],{"trials":437,"activeCount":66},[],{"intervention":439,"totalTrials":97,"cells":440},"Bemiparin sodium",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":460,"NA":462},{"trials":442,"activeCount":66},[],{"trials":444,"activeCount":66},[],{"trials":446,"activeCount":66},[],{"trials":448,"activeCount":66},[449],{"nctId":450,"briefTitle":451,"status":198,"phases":452,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT04604327","Comparison of Two Different Doses of Bemiparin in COVID-19",[57],"2021-05-31","2021-07-31","2020-10-26",164,[458],"COVID-19",[439],{"trials":461,"activeCount":66},[],{"trials":463,"activeCount":66},[],{"intervention":465,"totalTrials":62,"cells":466},"100 million Bone marrow mesenchimal stem cells",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":468,"activeCount":66},[],{"trials":470,"activeCount":66},[],{"trials":472,"activeCount":66},[473,484],{"nctId":474,"briefTitle":475,"status":72,"phases":476,"primaryCompletion":477,"completion":478,"start":291,"enrollment":115,"conditions":479,"interventions":481},"NCT02123368","Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells",[55,56],"2014-11","2015-02",[480],"Osteoarthritis",[482,483,465],"Hyaluronic acid","10 million Bone marrow mesenchimal stem cells",{"nctId":485,"briefTitle":486,"status":198,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT02365142","Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma",[55,56],"2018-06","2014-06",38,[492],"Knee Osteoarthritis",[465,494],"Platelet Rich plasma",{"trials":496,"activeCount":66},[],{"trials":498,"activeCount":66},[],{"trials":500,"activeCount":66},[],{"intervention":502,"totalTrials":62,"cells":503},"Nivolumab",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":505,"activeCount":66},[],{"trials":507,"activeCount":66},[],{"trials":509,"activeCount":66},[510,521],{"nctId":511,"briefTitle":512,"status":72,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":520},"NCT03380130","A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC",[56],"2020-03-01","2020-11-04","2017-09-11",41,[519],"Hepatocellular Carcinoma",[502],{"nctId":522,"briefTitle":523,"status":72,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},"NCT02550249","Neoadjuvant Nivolumab in Glioblastoma",[56],"2017-03","2015-06",29,[529],"Glioblastoma Multiforme",[502],{"trials":532,"activeCount":66},[],{"trials":534,"activeCount":66},[],{"trials":536,"activeCount":66},[],{"intervention":538,"totalTrials":97,"cells":539},"Hiltonol and autologous dendritic cells",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":541,"activeCount":66},[],{"trials":543,"activeCount":66},[],{"trials":545,"activeCount":66},[546],{"nctId":547,"briefTitle":548,"status":72,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT01734564","Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors",[56],"2016-12","2012-11",15,[554],"Neoplasms",[538],{"trials":557,"activeCount":66},[],{"trials":559,"activeCount":66},[],{"trials":561,"activeCount":66},[],{"intervention":563,"totalTrials":97,"cells":564},"Ivermectin",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":566,"activeCount":66},[],{"trials":568,"activeCount":66},[],{"trials":570,"activeCount":66},[571],{"nctId":572,"briefTitle":573,"status":72,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":583},"NCT04390022","Sars-CoV-2\u002FCOVID-19 Ivermectin Navarra-ISGlobal Trial",[56],"2020-09-17","2020-10-09","2020-07-31",24,[580,581,582],"Covid-19","Coronavirus Infection","SARS-CoV-2 Infection",[563],{"trials":585,"activeCount":66},[],{"trials":587,"activeCount":66},[],{"trials":589,"activeCount":66},[],{"intervention":591,"totalTrials":97,"cells":592},"autologous dendritic cells",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":594,"activeCount":66},[],{"trials":596,"activeCount":66},[],{"trials":598,"activeCount":66},[599],{"nctId":600,"briefTitle":601,"status":72,"phases":602,"primaryCompletion":603,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT01006044","Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection",[56],"2014-08","2009-10",26,[529],[591],{"trials":609,"activeCount":66},[],{"trials":611,"activeCount":66},[],{"trials":613,"activeCount":66},[],{"intervention":615,"totalTrials":97,"cells":616},"BO-112 in combination with ablative radiotherapy (SABR) and nivolumab",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":618,"activeCount":66},[],{"trials":620,"activeCount":66},[],{"trials":622,"activeCount":66},[623],{"nctId":624,"briefTitle":625,"status":198,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":115,"conditions":630,"interventions":632},"NCT05265650","Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC",[55,56],"2024-03","2024-06","2022-06-13",[631],"Non-Small Cell Lung Cancer Metastatic",[615],{"trials":634,"activeCount":66},[],{"trials":636,"activeCount":66},[],{"trials":638,"activeCount":66},[],{"intervention":640,"totalTrials":97,"cells":641},"Palonosetron",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":643,"activeCount":66},[],{"trials":645,"activeCount":66},[],{"trials":647,"activeCount":66},[648],{"nctId":649,"briefTitle":650,"status":72,"phases":651,"primaryCompletion":652,"completion":652,"start":604,"enrollment":527,"conditions":653,"interventions":655},"NCT01046240","Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy",[55,56],"2010-11",[654],"Emesis",[640],{"trials":657,"activeCount":66},[],{"trials":659,"activeCount":66},[],{"trials":661,"activeCount":66},[],{"intervention":663,"totalTrials":97,"cells":664},"Autologous dendritic cell vaccination",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":666,"activeCount":66},[],{"trials":668,"activeCount":66},[],{"trials":670,"activeCount":66},[671],{"nctId":672,"briefTitle":673,"status":72,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":527,"conditions":678,"interventions":681},"NCT01431196","Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer",[56],"2012-06","2013-12","2011-02",[679,680],"Stage II Breast Cancer","Stage III Breast Cancer",[663],{"trials":683,"activeCount":66},[],{"trials":685,"activeCount":66},[],{"trials":687,"activeCount":66},[],{"intervention":689,"totalTrials":97,"cells":690},"Autologous dendritic cells transduced with Ad encoding NS3",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":692,"activeCount":66},[],{"trials":694,"activeCount":66},[],{"trials":696,"activeCount":66},[697],{"nctId":698,"briefTitle":699,"status":387,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":707},"NCT02309086","Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C",[55,56],"2013-05","2014-05","2011-05",5,[706],"Hepatitis C, Chronic",[689],{"trials":709,"activeCount":66},[],{"trials":711,"activeCount":66},[],{"trials":713,"activeCount":66},[],{"intervention":715,"totalTrials":97,"cells":716},"Active",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":734,"PHASE4":736,"NA":738},{"trials":718,"activeCount":66},[],{"trials":720,"activeCount":66},[],{"trials":722,"activeCount":66},[723],{"nctId":724,"briefTitle":725,"status":72,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":578,"conditions":730,"interventions":732},"NCT02012387","Efficacy Study of Omalizumab in Cholinergic Urticaria",[56],"2016-09","2017-06","2014-01",[731],"Cholinergic Urticaria",[715,733],"Open labeled",{"trials":735,"activeCount":66},[],{"trials":737,"activeCount":66},[],{"trials":739,"activeCount":66},[],{"intervention":733,"totalTrials":97,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":743,"activeCount":66},[],{"trials":745,"activeCount":66},[],{"trials":747,"activeCount":66},[748],{"nctId":724,"briefTitle":725,"status":72,"phases":749,"primaryCompletion":727,"completion":728,"start":729,"enrollment":578,"conditions":750,"interventions":751},[56],[731],[715,733],{"trials":753,"activeCount":66},[],{"trials":755,"activeCount":66},[],{"trials":757,"activeCount":66},[],{"intervention":759,"totalTrials":97,"cells":760},"Tolcapone",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":762,"activeCount":66},[],{"trials":764,"activeCount":66},[],{"trials":766,"activeCount":66},[767],{"nctId":768,"briefTitle":769,"status":198,"phases":770,"primaryCompletion":771,"start":772,"enrollment":773,"conditions":774,"interventions":776},"NCT06387771","Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia",[56],"2025-08","2014-09-22",20,[775],"Schizophrenia",[759],{"trials":778,"activeCount":66},[],{"trials":780,"activeCount":66},[],{"trials":782,"activeCount":66},[],{"intervention":784,"totalTrials":97,"cells":785},"granisetron",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":787,"activeCount":66},[],{"trials":789,"activeCount":66},[],{"trials":791,"activeCount":66},[792],{"nctId":793,"briefTitle":794,"status":72,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":801},"NCT00450853","Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients",[56],"2005-11","2005-04",31,[800],"Vomiting",[784],{"trials":803,"activeCount":66},[],{"trials":805,"activeCount":66},[],{"trials":807,"activeCount":66},[],{"intervention":809,"totalTrials":97,"cells":810},"Octreotide",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":812,"activeCount":66},[],{"trials":814,"activeCount":66},[],{"trials":816,"activeCount":66},[817],{"nctId":818,"briefTitle":819,"status":198,"phases":820,"primaryCompletion":821,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":828},"NCT06085976","Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.",[56],"2025-08-14","2025-11-30","2023-08-14",62,[826,827],"Hepatic Carcinoma","Hepatic Metastasis",[809],{"trials":830,"activeCount":66},[],{"trials":832,"activeCount":66},[],{"trials":834,"activeCount":66},[],{"intervention":836,"totalTrials":97,"cells":837},"Follicular lymphoma, patient-specific, soluble protein idiotype vaccine",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":839,"activeCount":66},[],{"trials":841,"activeCount":66},[],{"trials":843,"activeCount":66},[844],{"nctId":845,"briefTitle":846,"status":198,"phases":847,"primaryCompletion":848,"completion":849,"start":226,"enrollment":430,"conditions":850,"interventions":853},"NCT00530140","Idiotypic Vaccination for Follicular Lymphoma Patients",[56],"2013-09","2022-09",[851,852],"Follicular Lymphoma","First Relapse\u002FProgression",[836],{"trials":855,"activeCount":66},[],{"trials":857,"activeCount":66},[],{"trials":859,"activeCount":66},[],{"intervention":482,"totalTrials":97,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":863,"activeCount":66},[],{"trials":865,"activeCount":66},[],{"trials":867,"activeCount":66},[868],{"nctId":474,"briefTitle":475,"status":72,"phases":869,"primaryCompletion":477,"completion":478,"start":291,"enrollment":115,"conditions":870,"interventions":871},[55,56],[480],[482,483,465],{"trials":873,"activeCount":66},[],{"trials":875,"activeCount":66},[],{"trials":877,"activeCount":66},[],{"intervention":483,"totalTrials":97,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":890,"PHASE4":892,"NA":894},{"trials":881,"activeCount":66},[],{"trials":883,"activeCount":66},[],{"trials":885,"activeCount":66},[886],{"nctId":474,"briefTitle":475,"status":72,"phases":887,"primaryCompletion":477,"completion":478,"start":291,"enrollment":115,"conditions":888,"interventions":889},[55,56],[480],[482,483,465],{"trials":891,"activeCount":66},[],{"trials":893,"activeCount":66},[],{"trials":895,"activeCount":66},[],{"intervention":897,"totalTrials":97,"cells":898},"Drug: Topical Rapamycin",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":900,"activeCount":66},[],{"trials":902,"activeCount":66},[],{"trials":904,"activeCount":66},[905],{"nctId":906,"briefTitle":907,"status":72,"phases":908,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":915},"NCT02080624","Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome",[56],"2012-09","2012-12","2011-01",23,[914],"Sturge- Weber Syndrome",[897],{"trials":917,"activeCount":66},[],{"trials":919,"activeCount":66},[],{"trials":921,"activeCount":66},[],{"intervention":923,"totalTrials":97,"cells":924},"Memantine",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":926,"activeCount":66},[],{"trials":928,"activeCount":66},[],{"trials":930,"activeCount":66},[931],{"nctId":932,"briefTitle":933,"status":387,"phases":934,"primaryCompletion":935,"completion":935,"start":936,"enrollment":773,"conditions":937,"interventions":939},"NCT00638833","Memantine Therapy for Multiple Sclerosis",[56],"2008-03","2007-09",[938],"Multiple Sclerosis",[923],{"trials":941,"activeCount":66},[],{"trials":943,"activeCount":66},[],{"trials":945,"activeCount":66},[],{"intervention":947,"totalTrials":97,"cells":948},"CP 675,206",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":963,"PHASE4":965,"NA":967},{"trials":950,"activeCount":66},[],{"trials":952,"activeCount":66},[],{"trials":954,"activeCount":66},[955],{"nctId":956,"briefTitle":957,"status":72,"phases":958,"primaryCompletion":291,"completion":291,"start":959,"enrollment":773,"conditions":960,"interventions":962},"NCT01008358","Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma",[56],"2008-12",[519,961],"Hepatitis C Virus Chronic Infection",[947],{"trials":964,"activeCount":66},[],{"trials":966,"activeCount":66},[],{"trials":968,"activeCount":66},[],{"intervention":494,"totalTrials":97,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":972,"activeCount":66},[],{"trials":974,"activeCount":66},[],{"trials":976,"activeCount":66},[977],{"nctId":485,"briefTitle":486,"status":198,"phases":978,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":979,"interventions":980},[55,56],[492],[465,494],{"trials":982,"activeCount":66},[],{"trials":984,"activeCount":66},[],{"trials":986,"activeCount":66},[],{"intervention":988,"totalTrials":97,"cells":989},"dendritic cells",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":991,"activeCount":66},[],{"trials":993,"activeCount":66},[],{"trials":995,"activeCount":66},[996],{"nctId":997,"briefTitle":998,"status":72,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":19,"conditions":1003,"interventions":1006},"NCT02496520","Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults",[55,56],"2018-09-16","2019-05-27","2014-09-30",[1004,1005],"Sarcoma","Central Nervous System Tumor",[988,1007],"Chemotherapy as needed by the patient´s tumor and stage",{"trials":1009,"activeCount":66},[],{"trials":1011,"activeCount":66},[],{"trials":1013,"activeCount":66},[],{"intervention":1007,"totalTrials":97,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":66},[],{"trials":1019,"activeCount":66},[],{"trials":1021,"activeCount":66},[1022],{"nctId":997,"briefTitle":998,"status":72,"phases":1023,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":19,"conditions":1024,"interventions":1025},[55,56],[1004,1005],[988,1007],{"trials":1027,"activeCount":66},[],{"trials":1029,"activeCount":66},[],{"trials":1031,"activeCount":66},[],{"intervention":1033,"totalTrials":97,"cells":1034},"Dendritic cells vaccine",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1036,"activeCount":66},[],{"trials":1038,"activeCount":66},[],{"trials":1040,"activeCount":66},[1041],{"nctId":1042,"briefTitle":1043,"status":198,"phases":1044,"primaryCompletion":201,"completion":201,"start":652,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT01348256","Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma",[56],58,[1047,827],"Colorectal Carcinoma",[1033],{"trials":1050,"activeCount":66},[],{"trials":1052,"activeCount":66},[],{"trials":1054,"activeCount":66},[],{"intervention":1056,"totalTrials":97,"cells":1057},"vismodegib",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1059,"activeCount":66},[],{"trials":1061,"activeCount":66},[],{"trials":1063,"activeCount":66},[1064],{"nctId":1065,"briefTitle":1066,"status":198,"phases":1067,"primaryCompletion":1068,"completion":201,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1072},"NCT02694224","Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients",[56],"2017-12","2016-04",40,[25],[1056,1073,1074,1075],"Paclitaxel","Epirubicin","Cyclophosphamide",{"trials":1077,"activeCount":66},[],{"trials":1079,"activeCount":66},[],{"trials":1081,"activeCount":66},[],{"intervention":1073,"totalTrials":97,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":66},[],{"trials":1087,"activeCount":66},[],{"trials":1089,"activeCount":66},[1090],{"nctId":1065,"briefTitle":1066,"status":198,"phases":1091,"primaryCompletion":1068,"completion":201,"start":1069,"enrollment":1070,"conditions":1092,"interventions":1093},[56],[25],[1056,1073,1074,1075],{"trials":1095,"activeCount":66},[],{"trials":1097,"activeCount":66},[],{"trials":1099,"activeCount":66},[],{"intervention":1074,"totalTrials":97,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1103,"activeCount":66},[],{"trials":1105,"activeCount":66},[],{"trials":1107,"activeCount":66},[1108],{"nctId":1065,"briefTitle":1066,"status":198,"phases":1109,"primaryCompletion":1068,"completion":201,"start":1069,"enrollment":1070,"conditions":1110,"interventions":1111},[56],[25],[1056,1073,1074,1075],{"trials":1113,"activeCount":66},[],{"trials":1115,"activeCount":66},[],{"trials":1117,"activeCount":66},[],{"intervention":1075,"totalTrials":97,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1121,"activeCount":66},[],{"trials":1123,"activeCount":66},[],{"trials":1125,"activeCount":66},[1126],{"nctId":1065,"briefTitle":1066,"status":198,"phases":1127,"primaryCompletion":1068,"completion":201,"start":1069,"enrollment":1070,"conditions":1128,"interventions":1129},[56],[25],[1056,1073,1074,1075],{"trials":1131,"activeCount":66},[],{"trials":1133,"activeCount":66},[],{"trials":1135,"activeCount":66},[],{"intervention":1137,"totalTrials":97,"cells":1138},"Urelumab + Nivolumab",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1140,"activeCount":66},[],{"trials":1142,"activeCount":66},[],{"trials":1144,"activeCount":66},[1145],{"nctId":1146,"briefTitle":1147,"status":198,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1153},"NCT03792724","Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors",[55,56],"2023-01-30","2019-01-30",32,[554],[1137],{"trials":1155,"activeCount":66},[],{"trials":1157,"activeCount":66},[],{"trials":1159,"activeCount":66},[],{"intervention":1161,"totalTrials":97,"cells":1162},"immunotherapy with dendritic cells",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1164,"activeCount":66},[],{"trials":1166,"activeCount":66},[],{"trials":1168,"activeCount":66},[1169],{"nctId":1170,"briefTitle":1171,"status":198,"phases":1172,"primaryCompletion":1173,"completion":402,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1180},"NCT00610389","Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors",[56],"2010-04","2008-02",27,[1177,1178,1179],"Renal Cell Carcinoma","Melanoma","Carcinoma, Hepatocellular",[1161],{"trials":1182,"activeCount":66},[],{"trials":1184,"activeCount":66},[],{"trials":1186,"activeCount":66},[],{"intervention":1188,"totalTrials":97,"cells":1189},"Autologous effector lymphocytes expanded ex-vivo",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1206,"PHASE4":1208,"NA":1210},{"trials":1191,"activeCount":66},[],{"trials":1193,"activeCount":66},[],{"trials":1195,"activeCount":66},[1196],{"nctId":1197,"briefTitle":1198,"status":198,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":490,"conditions":1202,"interventions":1205},"NCT01329354","Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy",[56],"2019-11","2011-03",[851,1203,1204],"Follicular Non-Hodgkin´s Lymphoma","Autologous Effector Lymphocytes",[1188],{"trials":1207,"activeCount":66},[],{"trials":1209,"activeCount":66},[],{"trials":1211,"activeCount":66},[],{"intervention":1213,"totalTrials":97,"cells":1214},"Sarilumab",{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1216,"activeCount":66},[],{"trials":1218,"activeCount":66},[],{"trials":1220,"activeCount":66},[1221],{"nctId":1222,"briefTitle":1223,"status":198,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT04661527","Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19",[56],"2020-12-30","2020-04-22",60,[1229],"COVID-19 Drug Treatment",[1213],{"trials":1232,"activeCount":66},[],{"trials":1234,"activeCount":66},[],{"trials":1236,"activeCount":66},[],{"intervention":1238,"totalTrials":97,"cells":1239},"TK99UN",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1253,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1241,"activeCount":66},[],{"trials":1243,"activeCount":66},[1244],{"nctId":1245,"briefTitle":1246,"status":72,"phases":1247,"primaryCompletion":1248,"completion":935,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1252},"NCT00844623","TK-based Suicide Gene Therapy for Hepatocellular Carcinoma",[55],"2003-11","2002-12",10,[1179],[1238],{"trials":1254,"activeCount":66},[],{"trials":1256,"activeCount":66},[],{"trials":1258,"activeCount":66},[],{"trials":1260,"activeCount":66},[],{"intervention":1262,"totalTrials":97,"cells":1263},"Endobronchial infusion of adult mesenchymal stem cells",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1285},{"trials":1265,"activeCount":66},[],{"trials":1267,"activeCount":66},[1268],{"nctId":1269,"briefTitle":1270,"status":72,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT01919827","Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis",[55],"2018-05-01","2013-03",17,[1276],"Idiopathic Pulmonary Fibrosis",[1262,1278],"Autologous mesenchymal stem cells derived from bone marrow",{"trials":1280,"activeCount":66},[],{"trials":1282,"activeCount":66},[],{"trials":1284,"activeCount":66},[],{"trials":1286,"activeCount":66},[],{"intervention":1278,"totalTrials":97,"cells":1288},{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1297,"PHASE3":1299,"PHASE4":1301,"NA":1303},{"trials":1290,"activeCount":66},[],{"trials":1292,"activeCount":66},[1293],{"nctId":1269,"briefTitle":1270,"status":72,"phases":1294,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1295,"interventions":1296},[55],[1276],[1262,1278],{"trials":1298,"activeCount":66},[],{"trials":1300,"activeCount":66},[],{"trials":1302,"activeCount":66},[],{"trials":1304,"activeCount":66},[],{"intervention":1306,"totalTrials":97,"cells":1307},"DNX-2440",{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1309,"activeCount":66},[],{"trials":1311,"activeCount":66},[1312],{"nctId":1313,"briefTitle":1314,"status":387,"phases":1315,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1322},"NCT03714334","DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma",[55],"2023-04-05","2018-10-16",16,[1320,1321],"Glioblastoma","Glioblastoma, Adult",[1306],{"trials":1324,"activeCount":66},[],{"trials":1326,"activeCount":66},[],{"trials":1328,"activeCount":66},[],{"trials":1330,"activeCount":66},[],{"intervention":1332,"totalTrials":62,"cells":1333},"Omalizumab",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1335,"activeCount":66},[],{"trials":1337,"activeCount":66},[],{"trials":1339,"activeCount":66},[1340],{"nctId":1341,"briefTitle":1342,"status":72,"phases":1343,"primaryCompletion":1344,"completion":728,"start":1345,"enrollment":773,"conditions":1346,"interventions":1348},"NCT01713725","Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria",[56],"2016-02","2012-03",[1347],"Chronic Urticaria",[1332],{"trials":1350,"activeCount":66},[],{"trials":1352,"activeCount":66},[],{"trials":1354,"activeCount":66},[1355],{"nctId":1356,"briefTitle":1357,"status":198,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT04665141","Similarities and Differences of Biological Therapies for Severe Asthma.",[],"2022-11","2021-04-07",600,[1363],"Asthma",[1365,1332,1366,1367,1368],"Mepolizumab","Reslizumab","Benralizumab","Dupilumab",{"intervention":1370,"totalTrials":97,"cells":1371},"Induction chemotherapy",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1373,"activeCount":66},[],{"trials":1375,"activeCount":66},[],{"trials":1377,"activeCount":66},[],{"trials":1379,"activeCount":66},[],{"trials":1381,"activeCount":66},[],{"trials":1383,"activeCount":66},[1384],{"nctId":1385,"briefTitle":1386,"status":72,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":848,"enrollment":229,"conditions":1389,"interventions":1394},"NCT02454647","Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients",[],"2015-03",[1390,1391,1392,23,1393],"Gastric Cancer","Adenocarcinoma","Effects of Chemotherapy","Gastrointestinal Neoplasms",[1370],{"intervention":1365,"totalTrials":97,"cells":1396},{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1398,"activeCount":66},[],{"trials":1400,"activeCount":66},[],{"trials":1402,"activeCount":66},[],{"trials":1404,"activeCount":66},[],{"trials":1406,"activeCount":66},[],{"trials":1408,"activeCount":66},[1409],{"nctId":1356,"briefTitle":1357,"status":198,"phases":1410,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1411,"interventions":1412},[],[1363],[1365,1332,1366,1367,1368],{"intervention":1366,"totalTrials":97,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1416,"activeCount":66},[],{"trials":1418,"activeCount":66},[],{"trials":1420,"activeCount":66},[],{"trials":1422,"activeCount":66},[],{"trials":1424,"activeCount":66},[],{"trials":1426,"activeCount":66},[1427],{"nctId":1356,"briefTitle":1357,"status":198,"phases":1428,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1429,"interventions":1430},[],[1363],[1365,1332,1366,1367,1368],{"intervention":1367,"totalTrials":97,"cells":1432},{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1434,"activeCount":66},[],{"trials":1436,"activeCount":66},[],{"trials":1438,"activeCount":66},[],{"trials":1440,"activeCount":66},[],{"trials":1442,"activeCount":66},[],{"trials":1444,"activeCount":66},[1445],{"nctId":1356,"briefTitle":1357,"status":198,"phases":1446,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1447,"interventions":1448},[],[1363],[1365,1332,1366,1367,1368],{"intervention":1368,"totalTrials":97,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1452,"activeCount":66},[],{"trials":1454,"activeCount":66},[],{"trials":1456,"activeCount":66},[],{"trials":1458,"activeCount":66},[],{"trials":1460,"activeCount":66},[],{"trials":1462,"activeCount":66},[1463],{"nctId":1356,"briefTitle":1357,"status":198,"phases":1464,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1361,"conditions":1465,"interventions":1466},[],[1363],[1365,1332,1366,1367,1368],{"intervention":1468,"totalTrials":97,"cells":1469},"Neoadjuvant chemotherapy",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1471,"activeCount":66},[],{"trials":1473,"activeCount":66},[],{"trials":1475,"activeCount":66},[],{"trials":1477,"activeCount":66},[],{"trials":1479,"activeCount":66},[],{"trials":1481,"activeCount":66},[1482],{"nctId":1483,"briefTitle":1484,"status":198,"phases":1485,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1493},"NCT06223763","SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery",[],"2024-06-01","2024-01-01",5000,[1490,1491,1492],"Epithelial Ovarian Cancer","Fallopian Tube Neoplasms","Peritoneal Neoplasms",[1468,1494],"Adjuvant chemotherapy",{"intervention":1494,"totalTrials":97,"cells":1496},{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1498,"activeCount":66},[],{"trials":1500,"activeCount":66},[],{"trials":1502,"activeCount":66},[],{"trials":1504,"activeCount":66},[],{"trials":1506,"activeCount":66},[],{"trials":1508,"activeCount":66},[1509],{"nctId":1483,"briefTitle":1484,"status":198,"phases":1510,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1488,"conditions":1511,"interventions":1512},[],[1490,1491,1492],[1468,1494]]